Table 2.
Cellular immunogenicity outcomes against wild-type SARS-CoV-2 after the third dose of CoronaVac in evaluable analysis population.
| Adolescents 3 doses |
Adults 3 doses |
|
|---|---|---|
| T cell responses | ||
| Total SNM-specific T cell responses on flow cytometry | ||
| N | 58 | 118 |
|
GM % IFN-γ+CD4+ T cells (95% CI) |
0.066% (0.041-0.106%) |
0.063% (0.045-0.089%) |
| % positive (>/=cut-off at 0.01%) | 74.1%, P=0.17 | 62.7% |
|
GM % IL-2+CD4+ T cells (95% CI) |
0.073% (0.049-0.109%) |
0.070% (0.052-0.093%) |
| % positive (>/=cut-off at 0.01%) | 79.3%, P=0.46 | 72.9% |
|
GM % IFN-γ+CD8+ T cells (95% CI) |
0.071% (0.040-0.125%) |
0.051% (0.035-0.075%) |
| % positive (>/=cut-off at 0.01%) | 62.1%, P=0.20 | 50.9% |
|
GM % IL-2+CD8+ T cells (95% CI) |
0.041% (0.027-0.063%) |
0.034% (0.026-0.044%) |
| % positive (>/=cut-off at 0.01%) | 65.5%, P=0.74 | 61.9% |
S, Spike; N, Nucleocapsid; M, Membrane; GM, geometric mean; CI, confidence interval; IFN-γ, interferon-gamma; IL-2, interleukin-2. P-values compare the proportion of positive responses between adolescents and adults by Fisher’s exact test.